Page 3
This amendment No. 1 (this “Amendment”) amends and supplements the Schedule
13D filed with the Securities and Exchange Commission (the “Commission”) on June 26, 2018 (the “Original Schedule 13D”) by the Reporting Persons relating to the ordinary shares, nominal value $0.000042 per share (the
“Ordinary Shares”), and the American Depositary Shares, each representing one Ordinary Share (the “ADSs” and together with the Ordinary Shares, the “Shares”) of Autolus Therapeutics plc, a company organized under the
laws of England and Wales (the “Issuer”).
Information reported in the Original Schedule 13D remains in effect except to the extent that it is
amended, restated or superseded by information contained in this Amendment. Capitalized terms used but not defined in this Amendment have the respective meanings set forth in the Original Schedule 13D. All references in the Original Schedule 13D and
this Amendment to the “Statement” will be deemed to refer to the Original Schedule 13D as amended and supplemented by this Amendment.
Item 4. Purpose of Transaction
Item 4 of the
Original Schedule 13D is hereby amended to add the following paragraph:
This Amendment is being filed to update the aggregate
percentage of Shares of the Issuer owned by the Reporting Persons due to changes caused by the issuance of additional Shares by the Issuer since the date of the Original Schedule 13D. Such transactions resulted in a decrease of over one percent (1%)
in the aggregate percentage ownership reported by the Reporting Persons in the Original Schedule 13D.
Item 5. Interest in Securities of the
Issuer
Item 5 of the Original Schedule 13D is hereby amended by adding the following paragraph and by amending Item 5(a) as follows:
The information reported below is based on a total of 52,298,876 Ordinary Shares outstanding as of September 30, 2020, as set forth in
Exhibit 99.1 to the Issuer’s Report of Foreign Private Issuer on Form 6-K, filed with the Commission on November 5, 2020. This Amendment is being filed to update the aggregate percentage of Shares of
the Issuer owned by the Reporting Persons due to changes caused by the issuance of additional Shares by the Issuer since the date of the Original Schedule 13D. Such transactions resulted in a decrease of over one percent (1%) in the aggregate
percentage ownership reported by the Reporting Persons in the Original Schedule 13D.
|
|
(a)
|
Item 7 through 11 and 13 of each of the cover pages of this Schedule 13D are incorporated herein by reference.
Arix Plc specifically disclaims beneficial ownership any securities reported herein that it does not directly own or control, except to the extent of its pecuniary interest therein.
|
Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer
Item 6 of the Schedule 13D is hereby amended to delete in its entirety the section titled “Board Representation.” Dr. Joseph Anderson, a
member of the Board of Directors of the Issuer, previously served as Chief Executive Officer and a member of the Board of Directors of Arix Plc, but as of October 3, 2020 is no longer employed by, or a member of the Board of Directors of, Arix
Plc or any of its subsidiaries.